SCHEMBL2556956

SCHEMBL2556956

COc1cc(NC(=O)Nc2cc(Cl)ccc2OC)c2ccccc2n1

nearest known ligand 0.81

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 8/20 0.81
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
GRIK1 P39086 1/20 0.58
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MAPT P10636 2/20 0.54
GAA P10253 1/20 0.54
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TP53 P04637 2/20 0.53
NTRK1 P04629 2/20 0.52
POLB P06746 1/20 0.52
NTRK2 Q16620 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29560611 0.89 IGF1R (1.00) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL2563976 0.89 IGF1R (1.00) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL31060203 0.89 IGF1R (1.00) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL4302397 0.77 IGF1R (0.79) IGF1RMEN1KMT2AKDM4EALDH1A1
SCHEMBL10221504 0.75 MEN1 (0.67) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL6588509 0.75 IGF1R (0.77) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL18500908 0.74 ALDH1A1 (0.74) MEN1KMT2AKDM4EALDH1A1NPSR1
SCHEMBL12316787 0.73 KMT2A (0.82) MEN1KMT2AGRIK1KDM4EALDH1A1
SCHEMBL1463298 0.73 GRIK1 (1.00) IGF1RMEN1KMT2AGRIK1KDM4E
SCHEMBL4317042 0.73 KMT2A (0.73) MEN1KMT2AALDH1A1NPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10799473-B2 Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2020-10-13 US claimed
US-20160000744-A1 Methods of Inhibiting IGF-1R Activation or Downtream Signalling Thereof to Reduce Radiation-Induced Cellular Senescence UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES 2016-01-07 US claimed
WO-2014137946-A1 METHODS OF INHIBITING IGF-1R ACTIVATION OR DOWNTREAM SIGNALLING THEREOF TO REDUCE RADIATION-INDUCED CELLULAR SENESCENCE THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2014-09-12 WO claimed
WO-2011133668-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-10-27 WO claimed
US-11319376-B2 Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer REMD BIOTHERAPEUTICS, INC. (US) 2022-05-03 US disclosed
US-10799473-B2 Methods of inhibiting IGF-1R activation or downtream signalling thereof to reduce radiation-induced cellular senescence THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2020-10-13 US disclosed
EP-3493847-A2 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER REMD Biotherapeutics, Inc. (US) 2019-06-12 EP disclosed
US-20190169300-A1 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER REMD Biotherapeutics, Inc 2019-06-06 US disclosed
WO-2018027084-A2 COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER REMD BIOTHERAPEUTICS, INC. (US) 2018-02-08 WO disclosed
US-20160000744-A1 Methods of Inhibiting IGF-1R Activation or Downtream Signalling Thereof to Reduce Radiation-Induced Cellular Senescence UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES 2016-01-07 US disclosed
WO-2014137946-A1 METHODS OF INHIBITING IGF-1R ACTIVATION OR DOWNTREAM SIGNALLING THEREOF TO REDUCE RADIATION-INDUCED CELLULAR SENESCENCE THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2014-09-12 WO disclosed
WO-2011133668-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-10-27 WO disclosed